| Jul 2 |
Semnur Pharmaceuticals and Denali Capital Acquisition enter into a letter of intent for proposed business combination
|
| Jul 2 |
Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, and Denali Capital Acquisition Corp. (Nasdaq: DECA) Enter into a Letter of Intent for a Proposed Business Combination
|
| Jul 2 |
Scilex Holding Company to Ring Nasdaq Closing Bell on Friday, July 5th at 4:00PM ET at the Nasdaq MarketSite in Times Square, New York
|
| Jul 1 |
Scilex says total product net sales for June grew in the range of 77% to 116%
|
| Jul 1 |
Scilex Holding Company Provides Certain Preliminary Unaudited Financial Results for the Month Ended June 30, 2024 and Second Quarter of 2024
|
| Jun 20 |
Scilex Holding Company Partners with New National Distributor, Endeavor Distribution LLC.
|
| Jun 14 |
Scilex Holding Company Announces Publication in PAIN Journal Regarding Phase 3 Results of the Pivotal Registration Trial of SP-102 (SEMDEXA™) in Lumbosacral Radicular Pain (Sciatica)
|
| Jun 14 |
Scilex Holding Company (NASDAQ:SCLX) Analysts Just Cut Their EPS Forecasts Substantially
|
| Jun 13 |
Scilex Holding Company to Present Poster on ELYXYB® (celecoxib oral solution) at the 66th Annual Scientific Meeting of the American Headache Society (AHS) to be Held in San Diego, CA on June 13-16, 2024
|
| Jun 11 |
Scilex Holding Company Announces 5-Year Term of $100 Million Financing with Royalty-Based Payments and Potential Strategic Transactions with Perigrove and its Portfolio Companies
|
